K
Kenneth S. Hu
Researcher at University of York
Publications - 135
Citations - 2292
Kenneth S. Hu is an academic researcher from University of York. The author has contributed to research in topics: Radiation therapy & Head and neck cancer. The author has an hindex of 22, co-authored 123 publications receiving 1876 citations. Previous affiliations of Kenneth S. Hu include Beth Israel Deaconess Medical Center & Albert Einstein College of Medicine.
Papers
More filters
Journal ArticleDOI
Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial
Nancy Y. Lee,Qiang Zhang,David G. Pfister,John Kim,Adam S. Garden,James Mechalakos,Kenneth S. Hu,Q.T. Le,A. Dimitrios Colevas,Bonnie S. Glisson,Anthony T.C. Chan,K. Kian Ang +11 more
TL;DR: In this article, the feasibility and safety of the addition of bevacizumab to chemoradiotherapy was evaluated for stage IIB-IVB nasopharyngeal carcinoma from 19 centres in North America and Hong Kong.
Journal ArticleDOI
High-dose-rate intraoperative radiation therapy (HDR-IORT) for retroperitoneal sarcomas ☆
TL;DR: The purpose of this study was to determine if the addition of high-dose-rate intraoperative radiation therapy (HDR-IORT) to surgery and external beam radiotherapy (EBRT) would improve the outcome in retroperitoneal sarcoma patients and is encouraged by the favorable local control rate and the acceptable morbidity.
Journal ArticleDOI
Paradigm shifts in the management of osteoradionecrosis of the mandible
TL;DR: Since the introduction of Marx's protocol, there have been advances in surgical techniques, as well as in imaging techniques, which have significantly impacted on the diagnosis and management of ORN.
Journal Article
Radiotherapy in the management of plasma cell tumors.
Kenneth S. Hu,Joachim Yahalom +1 more
TL;DR: The rationale for and various aspects of providing effective radiotherapy in patients with plasma cell tumors are explored.
Journal ArticleDOI
Phase 1b, multicenter, single blinded, placebo-controlled, sequential dose escalation study to assess the safety and tolerability of topically applied AG013 in subjects with locally advanced head and neck cancer receiving induction chemotherapy
Sewanti Limaye,Robert I. Haddad,Fiona Cilli,Stephen T. Sonis,A. Dimitrios Colevas,Michael T. Brennan,Kenneth S. Hu,Barbara A. Murphy +7 more
TL;DR: The safety and tolerability of AG013, an oral rinse containing recombinant Lactococcus lactis secreting mucosal protectant human trefoil factor 1 (hTFF1), was evaluated in a phase 1b study in LAHNC subjects who received induction with cisplatin, 5‐fluorouracil, with or without docetaxel.